AU2022218110A1 - Composition and methods for treating cancer - Google Patents

Composition and methods for treating cancer Download PDF

Info

Publication number
AU2022218110A1
AU2022218110A1 AU2022218110A AU2022218110A AU2022218110A1 AU 2022218110 A1 AU2022218110 A1 AU 2022218110A1 AU 2022218110 A AU2022218110 A AU 2022218110A AU 2022218110 A AU2022218110 A AU 2022218110A AU 2022218110 A1 AU2022218110 A1 AU 2022218110A1
Authority
AU
Australia
Prior art keywords
cancer
methylenediamine
pharmaceutically acceptable
subject
dihydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022218110A
Other languages
English (en)
Inventor
Yanping Kong
Jinhong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2022218110A1 publication Critical patent/AU2022218110A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/132Amines having two or more amino groups, e.g. spermidine, putrescine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022218110A 2021-02-02 2022-01-28 Composition and methods for treating cancer Pending AU2022218110A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144690P 2021-02-02 2021-02-02
US63/144,690 2021-02-02
PCT/US2022/014379 WO2022169690A1 (en) 2021-02-02 2022-01-28 Composition and methods for treating cancer

Publications (1)

Publication Number Publication Date
AU2022218110A1 true AU2022218110A1 (en) 2023-08-17

Family

ID=82742455

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022218110A Pending AU2022218110A1 (en) 2021-02-02 2022-01-28 Composition and methods for treating cancer

Country Status (8)

Country Link
US (1) US20240099992A1 (https=)
EP (1) EP4288040A4 (https=)
JP (1) JP2024506999A (https=)
KR (1) KR20230142733A (https=)
CN (1) CN117083061A (https=)
AU (1) AU2022218110A1 (https=)
CA (1) CA3209477A1 (https=)
WO (1) WO2022169690A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560522A1 (en) * 2003-03-26 2004-10-07 Recepticon Aps Use of compounds for the prevention of drug-induced cell toxicity
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
AU2006275702A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
KR101380190B1 (ko) 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔d〕〔1,3〕―디옥솔 유도체
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
JPWO2011002026A1 (ja) * 2009-06-30 2012-12-13 国立大学法人 熊本大学 アミロイド線維形成抑制剤及びその利用
RU2417999C2 (ru) * 2009-07-13 2011-05-10 Закрытое Акционерное Общество "Ива Фарм" БИЯДЕРНЫЕ КООРДИНАЦИОННЫЕ СОЕДИНЕНИЯ БИОЛОГИЧЕСКИ АКТИВНЫХ d-ЭЛЕМЕНТОВ С АЛИФАТИЧЕСКИМИ ТИОЛАМИ КАК СРЕДСТВА ПОВЫШЕНИЯ ЭФФЕКТИВНОСТИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ
JP2011084541A (ja) * 2009-10-19 2011-04-28 Ltt Bio-Pharma Co Ltd 低分子薬物含有ナノ粒子
CA3064486C (en) 2017-04-20 2023-08-01 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivatives
GB201804924D0 (en) * 2018-03-27 2018-05-09 Univ Oxford Innovation Ltd Radiolabelled compound

Also Published As

Publication number Publication date
KR20230142733A (ko) 2023-10-11
US20240099992A1 (en) 2024-03-28
CA3209477A1 (en) 2022-08-11
CN117083061A (zh) 2023-11-17
JP2024506999A (ja) 2024-02-15
EP4288040A1 (en) 2023-12-13
EP4288040A4 (en) 2025-01-08
WO2022169690A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
US20210085649A1 (en) Methods and use of compounds that bind to rela of nf-kb
US10266505B2 (en) Compositions and methods for treating cancers
CN104968358B (zh) 涉及粘液素的疾病治疗
WO2019217164A1 (en) Compositions and methods for treating cancer and other diseases
NL8301913A (nl) Middel voor het versterken van de antitumor activiteit van een middel tegen tumoren.
US20250275938A1 (en) Compositions and methods for treatment of cancer
US20240099992A1 (en) Compositions and methods for treating cancer
US20150110774A1 (en) S100 protein inhibitors for treating leukemia
KR20180117681A (ko) 글리코알칼로이드 조합 및 그의 다양한 용도
US20180055915A1 (en) Compositions and methods for treating prostate cancer
JP2020524681A (ja) 血液ガンのためのmcl−1阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
WO2017079003A1 (en) Deuterated compounds for treating blood cancers, and compositions and methods thereof
KR20200121251A (ko) 항암제의 병용투여용 약학조성물
HK40103289A (zh) 用於治疗癌症的组合物和方法
CN115634228B (zh) 嘌呤合成抑制剂在制备治疗缺血和缺血再灌注损伤药物中的应用
FR2910813A1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2016073733A1 (en) Methods of treating cancer using lipopeptides
WO2021226033A1 (en) Hyaluronic acid drug conjugates
WO2021229832A1 (ja) ベネトクラクスの水溶性高分子誘導体